News

OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.

Ophthalmologists are now armed with new therapies to fight retinal disease.

In an effort to educate the public on GA, Prevent Blindness has created a variety of resources for patients in English and Spanish.

Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.

According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.

According to physician, this therapeutic may prove to be a treatment option for these diseases.

Investigators examining end-stage RP witness the partial visual recovery in 2 patients.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

Despite the latest advances in anti-VEGF therapy, a small group of patients do not achieve improved vision. Ophthalmologists are looking for options.

Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and imaging datasets.

According to physicians, patients who do not undergo second procedure are more likely to develop glaucoma.

The funding will give a boost to the development of the company's novel photo-crosslinked EyeLief, EyeLief-SD, and OcuLie biodegradable drug-delivery technologies.

In an effort to educate the public on geographic atrophy, Prevent Blindness has created a variety of resources in English and Spanish.

The company is currently developing sustained release ophthalmic therapeutics aimed at reducing the frequency of intravitreal injections required to treat a wide range of retinal diseases.

Re-Vana has demonstrated that its platform can achieve 6 months or greater sustained delivery of an anti-VEGF biologic at therapeutically-relevant levels with high drug loading, controlled burst release, and a favorable degradation profile.

The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

Contemporary scleral lenses work so well that stable vision in them cannot necessarily be taken as a sign that KC progression has stopped. Determination of KC progression requires advanced imaging.

The groups invite those attending the annual conference to join them at their event on Monday, January 16, which is free to OWL and WIO members.

According to investigators, the risk for the development of dry eye disease is greater in postmenopausal women compared with those who have not reached menopause as a result of hormonal dysregulation of the ocular secretory glands.

According to investigators, retinal aging caused by stress produces symptoms similar to those resulting from natural aging.

Investigators who are examining end-stage disease see significant visual recovery in 2 patients.

Investigators find a link with a postoperative prolonged steroid response.

Patients surveyed say the handheld tool proved to be comfortable and easy to use.